3-amino-pyrazole derivatives for tuberculosis treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis treatments are inadequate due to the rise of multi-drug resistant strains and the need for shorter, less frequent dosing regimens that prevent resistance, with existing vaccines and therapies failing to protect against Mycobacterium tuberculosis effectively.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, which is a heteroaromatic ring-based compound targeting the InhA enzyme in Mycobacterium tuberculosis, not requiring activation by KatG, to provide an alternative to isoniazid and combat multi-drug resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current tuberculosis therapy uses combination therapy with isoniazid and rifampin for six months, then treatment effectiveness is maintained, but treatment duration is too long and daily dosing is required which drives resistance emergence
Solution Approach 1:
The patent changes the pharmacological parameters by introducing a novel compound (Formula I) with modified chemical structure that targets InhA enzyme directly without requiring KatG activation. This new compound has different dosing frequency requirements and resistance profiles compared to traditional isoniazid, enabling shorter treatment durations while maintaining effectiveness against resistant strains.
Solution Approach 2:
The patent uses an intermediary approach by developing a compound that acts as a direct InhA inhibitor, bypassing the need for KatG activation that is required for isoniazid. This intermediary mechanism (direct InhA binding) allows for alternative treatment regimens that reduce daily dosing requirements and minimize resistance selection pressure.
2Reliability
If isoniazid is used as frontline therapy, then treatment effectiveness is achieved, but multi-drug resistant strains emerge due to poor compliance and long treatment duration
Solution Approach 1:
The patent converts the harmful effect of InhA enzyme inhibition (which causes resistance when used long-term with isoniazid) into a beneficial direct-targeting mechanism. The novel compound Formula I provides selective InhA inhibition that can be achieved at lower doses and with less frequent administration, transforming the resistance problem into an opportunity for newer, more resistant-proof therapy.
Solution Approach 2:
Instead of using isoniazid which requires activation by KatG and has poor compliance-driven resistance, the patent inverts the approach by using a directly-acting InhA inhibitor that does not require bacterial enzyme activation. This inversion of the activation mechanism fundamentally changes how resistance develops and allows for shorter, more compliant treatment regimens.
3Ease of operation
If daily dosing is required for six months, then treatment compliance is challenging, but shorter courses with less frequent dosing are needed to prevent resistance
Solution Approach 1:
The patent implements periodic action by designing a treatment regimen with less frequent dosing intervals. The novel compound Formula I allows for extended-interval dosing (e.g., twice weekly or monthly) compared to daily isoniazid dosing, making treatment more manageable for patients while maintaining therapeutic effectiveness through sustained InhA inhibition.
Solution Approach 2:
The patent introduces dynamics into treatment by allowing flexible dosing schedules that adapt to patient needs. The compound's pharmacokinetic properties enable dynamic adjustment of dosing frequency and timing, transitioning from rigid daily dosing to more flexible periodic dosing that improves compliance without compromising treatment outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively targets InhA, offering a potential replacement for isoniazid in tuberculosis therapy, capable of killing resistant strains and providing a shorter, less frequent treatment option, thereby addressing the limitations of current therapies.
Implementation Method 1
The enzyme which is denoted 'InhA' is an NADH-dependent (dependent on the reduced form of nicotinamide adenine dinucleotide), 2-trans enoyl-ACP (acyl carrier protein) reductase of the type 2 fatty acid synthesis (FASII) pathway in Mycobacterium tuberculosis. The drug inhibits InhA enzymatic activity inducing an accumulation of saturated C24-C26 fatty acids and blocking the production of longer molecules, including mycolic acids.
Implementation Method 2
The activated form is thought to react covalently with NADH within the InhA active site to form an inhibitory adduct.
Data Source
AI summary
A compound of Formula (I) or a pharmaceutically acceptable salt thereof:Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.